Drugs.com New Drug ApplicationsOriginal article
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility
BLA FilingApitegromabPositive
AI Analysis
Summary
Scholar Rock announced that FDA review of its apitegromab BLA for spinal muscular atrophy will progress with a second fill-finish facility. The announcement indicates regulatory progress on the manufacturing side of the application.
Outcome Details
FDA review of BLA to progress with second fill-finish facility
Importance:7/10
Sentiment:
0.60
FDABLASMAneuromuscular diseasebiologicsmanufacturing
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on August 7, 2026 11:08 PM